PT - JOURNAL ARTICLE AU - Aggrey Semeere AU - Helen Byakwaga AU - Miriam Laker-Oketta AU - Esther Freeman AU - Naftali Busakhala AU - Megan Wenger AU - Charles Kasozi AU - Matthew Ssemakadde AU - Mwebesa Bwana AU - Michael Kanyesigye AU - Philippa Kadama-Makanga AU - Elyne Rotich AU - Job Kisuya AU - Edwin Sang AU - Kara Wools-Kaloustian AU - Toby Maurer AU - Andrew Kambugu AU - Jeffrey Martin TI - Feasibility of Rapid Case Ascertainment for Cancer in East Africa: An Investigation of Community-Representative Kaposi Sarcoma in the Era of Antiretroviral Therapy AID - 10.1101/2021.05.21.21257178 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.21.21257178 4099 - http://medrxiv.org/content/early/2021/05/24/2021.05.21.21257178.short 4100 - http://medrxiv.org/content/early/2021/05/24/2021.05.21.21257178.full AB - BACKGROUND Rapid case ascertainment (RCA) refers to the expeditious and detailed examination of patients with a potentially rapidly fatal disease shortly after diagnosis. RCA is frequently performed in resource-rich settings to facilitate cancer research. Despite its utility, RCA is rarely implemented in resource-limited settings and has not been performed for malignancies. One cancer and context that would benefit from RCA in a resource-limited setting is HIV-related Kaposi sarcoma (KS) in sub-Saharan Africa.METHODS To determine the feasibility of RCA of KS, we searched for all potential newly diagnosed KS among HIV-infected adults attending three community-based facilities in Uganda and Kenya. Searching involved querying of electronic medical records, pathology record review, and notification by clinicians. Upon identification, a team verified eligibility and attempted to locate patients to perform RCA, which included epidemiologic, clinical and laboratory measurements.RESULTS We identified 593 patients with suspected new KS. Of the 593, 171 were ineligible, mainly because biopsy failed to confirm KS (65%) or KS was not new (30%). Among the 422 remaining, RCA was performed within 1 month for 56% of patients and within 3 months for 65% (95% confidence interval: 59 to 70%). Reasons for not performing RCA included intervening death (47%), inability to contact (44%), refusal/unsuitable to consent (8.3%), and patient re-location (0.7%).CONCLUSIONS We found that RCA — an important tool for cancer research in resource-rich settings — is feasible for the investigation of community-representative KS in East Africa. Feasibility of RCA for KS suggests feasibility for other cancers in Africa.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was supported by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute (NCI) in accordance with the regulatory requirements of the National Institutes of Health under Award Numbers U01AI069911 (East Africa IeDEA Consortium), U54 CA190153, U54 CA254571 and P30 AI027763. The funders did not have a role in design of the study, analysis, interpretation of data, or in writing the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study had regulatory approval in both Kenya and Uganda. In Kenya the study was approved by the Institutional Research Ethics Committee (IREC) at Moi University in Eldoret, (Protocol No. 0001827) and in Uganda by the Makerere University College of Health Sciences School of Biomedical Sciences Higher Degrees Research and Ethics Committee (Protocol No. SBS-HD-REC-495) and the Uganda National Council of Science and Technology (UNCST) (Protocol No. HS157ES).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and analyzed during the current study are available from the corresponding author on reasonable request.